0
0 (0%)
20/20 Global, Inc. [TPIA]
Source:
Company Overview
Mycotopia Therapies, Inc. promotes the study of psychedelics for the treatment of mental health issues and supports the creation of both natural and synthetic molecules for the development of appropriate treatments. Through its investment in Psychedelitech, it sponsors conferences regarding the legal psychedelics industry. Mycotopia also intends to deploy technology from its parent company, Ehave, Inc., in the collection of research and clinical data to further the study of the effects of psychedelics in the treatment of mental health issues.
| Country | United States |
| Headquarters | heyburn, idaho |
| Phone Number | 208-677-2020 |
| Industry | wholesale |
| CEO | Benjamin Kaplan, |
| Website | clinicaltrials.gov |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-1.6 |
| Net Income | $-1.8 |
| Net Cash | $-0.1 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -100.6% |
| Profit as % of Stockholder Equity |
Management Effectiveness
| Return on Equity | |
| Return on Assets | -126.9% |
| Turnover Ratio | |
| EBITA | $-1.6 |
Balance Sheet and Cash Flow Measures
| Total Assets | $1.5 |
| Total Liabilities | $4.9 |
| Operating Cash Flow | $-0.3 |
| Investing Cash Flow | |
| Financing Cash Flow | $0.2 |
